{
    "clinical_study": {
        "@rank": "107751", 
        "acronym": "McCP2/3", 
        "arm_group": [
            {
                "arm_group_label": "MC-1101 active", 
                "arm_group_type": "Experimental", 
                "description": "Topical Drug   1% Ophthalmic Solution Topically, two times per day; morning and bedtime"
            }, 
            {
                "arm_group_label": "MC-1101 Vehicle Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Topical Drug:\nOphthalmic Solution Topically, two times per day; morning and bedtime"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase II/III,vehicle controlled, double masked, single center study. A single eye\n      of 60 individuals with mild to moderate non-exudative Age-Related Macular Degeneration (AMD)\n      will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2\n      years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for\n      these patients.\n\n      An analysis of the primary and secondary endpoints will be conducted when all subjects have\n      completed Baseline, 1, 3, 6, 12,18 and 24 months."
        }, 
        "brief_title": "Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Exudative Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Geographic Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "MC-1101is a topically administered drug which in previous clinical studies has been proven\n      to get to the back of the eye. MC-1101is a 505 (b) 2 compound and has FDA Fast Track Status.\n      It is a strong, vasoactive drug which is intended to increase choroidal blood flow."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females age \u2265 50 years and \u2264 85 years\n\n          -  Females only: At least 1year since last menstrual period or surgically sterilized\n\n          -  20/80 or better ETDRS best corrected visual acuity\n\n          -  Early to intermediate nonexudative AMD (AMD category 3 through 3b on Age-Related Eye\n             Disease Study (AREDS) Report No. 8 AMD Categories\n\n          -  Willing and able to sign informed consent, comply with study protocol requirements,\n             and   undergo at least 2.5 hours of testing at each visit\n\n          -  Able to reliably to complete biophysical testing\n\n          -  Willing to take an AREDS2 based formula vitamin as indicated\n\n        Exclusion Criteria:\n\n          -  Past or current exudative AMD or central  geographic atrophy in study eye; (AMD\n             Category 4 on Age-Related Eye Disease Study (AREDS) Report No. 8 AMD Categories)\n\n          -  Past or current retinal or choroidal vasculopathy in study eye (e.g. serous or\n             hemorrhagic pigment epithelial detachment, polypoidal choroidal vasculopathy, central\n             serous chorioretinopathy, retinal vein occlusion, sickle cell retinopathy)\n\n          -  Uncontrolled hypertension (\u2265 160 systolic or \u226595 diastolic)\n\n          -  Glaucoma\n\n          -  Dilated pupil diameter less than 6 millimeters\n\n          -  Subjects with a history of a hypersensitivity reaction to the study drug or to any\n             agent used in the components of the study assessment\n\n          -  Use of topical ocular medications (other than artificial tear products)\n\n          -  Anticipated extra- or intraocular intervention during the study period\n\n          -  High myopia (refractive error spherical equivalent \u2265 -6 diopters)\n\n          -  Optic neuropathy\n\n          -  Neurological conditions that can impair vision (e.g. Parkinson's disease, multiple\n             sclerosis, Alzheimer's disease)\n\n          -  Liver disease (e.g. cirrhosis, hepatitis)\n\n          -  History of small bowel surgery\n\n          -  Current or past use for more than 30 days of chloroquine, hydroxychloroquine,\n             chlorpromazine, thioridazine, quinine sulfate, clofazimine, cisplatin, carmustine\n             (BCNU), deferoxamine, amiodorone, isoretinoin, or gold\n\n          -  Contact lens wearers (not prepared to discontinue lens use)\n\n          -  Ophthalmic surgery of any kind within 3 months prior to screening visit\n\n          -  Participation in any interventional clinical study requiring IRB approval within 3\n             months prior to screening visit of this study\n\n          -  Currently being treated for cancer or any disease likely to adversely affect\n             participation in a 2 year study\n\n          -  Known to have AIDS/HIV\n\n          -  Current use of hydralazine\n\n          -  Any other findings deemed unacceptable by the Principal Investigator or Sponsor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127463", 
            "org_study_id": "MC-1101-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "MC-1101 active", 
                "description": "Topically, two times a day, morning and bedtime", 
                "intervention_name": "MC-1101", 
                "intervention_type": "Drug", 
                "other_name": "1% Ophthalmic Solution"
            }, 
            {
                "arm_group_label": "MC-1101 Vehicle Control", 
                "description": "Topically, two times a day; morning and bedtime", 
                "intervention_name": "MC-1101 Vehicle", 
                "intervention_type": "Drug", 
                "other_name": "Topical Ophthalmic Solution"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AMD", 
            "Dry AMD", 
            "Non-Exudative AMD", 
            "MC-1101"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "kmrasmussen@yahoo.com", 
                "last_name": "Kari Rasmussen, BS", 
                "phone": "801-264-4444"
            }, 
            "contact_backup": {
                "email": "katie.roach@rockymountainretina.com", 
                "last_name": "Katie Roach, RN", 
                "phone": "8012644444"
            }, 
            "facility": {
                "address": {
                    "city": "Murray", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84107"
                }, 
                "name": "Rocky Mountain Retina Consultants"
            }, 
            "investigator": {
                "last_name": "Mitchell J Goff, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration", 
        "overall_contact": {
            "email": "pralston@macuclear.com", 
            "last_name": "Philip G Ralston, MBA", 
            "phone": "2145775999"
        }, 
        "overall_contact_backup": {
            "email": "mmmgoff@yahoo.com", 
            "last_name": "Mitchell J Goff, MD", 
            "phone": "8012644444"
        }, 
        "overall_official": {
            "affiliation": "Rocky Mountain Retina Consultants", 
            "last_name": "Mitchell J Goff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy assessment will be a comparison between groups of the change in visual function at 12 months with additional analyses at 18 and 24 months measured by dark adaptation methodology.", 
            "measure": "Visual Function", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127463"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the safety and tolerability (incidence and severity of adverse events, ocular irritability and ocular hyperemia) of MC-1101compared to a vehicle control at each study visit following treatment for 2 years.", 
            "measure": "Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 24 months"
        }, 
        "source": "MacuCLEAR, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MacuCLEAR, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}